229 related articles for article (PubMed ID: 29887238)
1. FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.
Pecqueux C; Arslan A; Heller M; Falkenstein M; Kaczorowski A; Tolstov Y; Sültmann H; Grüllich C; Herpel E; Duensing A; Kristiansen G; Hohenfellner M; Navone NM; Duensing S
Urol Oncol; 2018 Aug; 36(8):365.e15-365.e26. PubMed ID: 29887238
[TBL] [Abstract][Full Text] [Related]
2. FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57.
Cuevas R; Korzeniewski N; Tolstov Y; Hohenfellner M; Duensing S
Cancer Res; 2013 Feb; 73(4):1400-10. PubMed ID: 23243019
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Yang F; Strand DW; Rowley DR
Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
[TBL] [Abstract][Full Text] [Related]
4. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.
Fong EL; Wan X; Yang J; Morgado M; Mikos AG; Harrington DA; Navone NM; Farach-Carson MC
Biomaterials; 2016 Jan; 77():164-72. PubMed ID: 26599623
[TBL] [Abstract][Full Text] [Related]
5. Exogenous fibroblast growth factors maintain viability, promote proliferation, and suppress GADD45alpha and GAS6 transcript content of prostate cancer cells genetically modified to lack endogenous FGF-2.
Shain SA
Mol Cancer Res; 2004 Nov; 2(11):653-61. PubMed ID: 15561781
[TBL] [Abstract][Full Text] [Related]
6. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
Giri D; Ropiquet F; Ittmann M
Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
8. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
[TBL] [Abstract][Full Text] [Related]
9. Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.
Liu J; You P; Chen G; Fu X; Zeng X; Wang C; Huang Y; An L; Wan X; Navone N; Wu CL; McKeehan WL; Zhang Z; Zhong W; Wang F
Oncogene; 2016 Apr; 35(14):1750-9. PubMed ID: 26096936
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
11. Widespread telomere instability in prostatic lesions.
Tu L; Huda N; Grimes BR; Slee RB; Bates AM; Cheng L; Gilley D
Mol Carcinog; 2016 May; 55(5):842-52. PubMed ID: 25917938
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
13. Landscape of chromosome number changes in prostate cancer progression.
Braun M; Stomper J; Kirsten R; Adler D; Vogel W; Böhm D; Wernert N; Kristiansen G; Perner S
World J Urol; 2013 Dec; 31(6):1489-95. PubMed ID: 23512229
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
Wan X; Corn PG; Yang J; Palanisamy N; Starbuck MW; Efstathiou E; Li Ning Tapia EM; Zurita AJ; Aparicio A; Ravoori MK; Vazquez ES; Robinson DR; Wu YM; Cao X; Iyer MK; McKeehan W; Kundra V; Wang F; Troncoso P; Chinnaiyan AM; Logothetis CJ; Navone NM
Sci Transl Med; 2014 Sep; 6(252):252ra122. PubMed ID: 25186177
[TBL] [Abstract][Full Text] [Related]
15. [Expression and its significance of b-FGF in human benign prostatic hyperplasia and prostatic carcinoma tissues].
Wang FL; Wang H; Qin WJ; Wu GJ; Zhang G; Li KN
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Mar; 20(2):203-5. PubMed ID: 15191726
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.
West AF; O'Donnell M; Charlton RG; Neal DE; Leung HY
Br J Cancer; 2001 Aug; 85(4):576-83. PubMed ID: 11506499
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
